The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.

What the trial testedas reported · 4,754 people · 2019

Range includes no effect

2.9×0.8× to 9.6×

Bigger than 9 in 10 for adverse events & safety

As reported

OR 2.85, 95% CI 0.84–9.62

the abstract, start to end

… who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 2.850.84–9.62

GLP-1 receptor agonistsAdverse events & safety

1 / 3

2019

2020

2021

2022

2023

2024

2025

this paperpooled itcites it